Allied BioScience is governed by a distinguished board of directors who bring seasoned corporate experience and vision to ABS to assist in product development and business management. ABS’ board leverages this experience toward the common goal of creating best practices in breaking the chain of infection through the development of long-lasting antimicrobial technology.
Chairman of the Board
Keith is currently director and chairman of Century Bridge Capital, a real estate investment firm with offices in Dallas, Texas, and Beijing, China. He served as chairman and CEO of Waddell & Reed Financial Inc., a publicly held mutual fund complex (NYSE: WDR), bringing the firm’s assets under his management from $5 billion to more than $40 billion. Prior to this, Keith served as vice chairman of the board of Torchmark Corporation, a publicly held insurance, financial services and real estate development company (NYSE: TMK) and as a partner with KPMG Peat Marwick.
Hugh (Nick) Dallas
Nick has served as director of Environmental Service Professionals Inc. and holds a Branch II and III operator’s license from the California Structural Pest Control Board. He is a member of the Indoor Environmental Standards Organization and is a certified IESO trainer. He assists ABS with field operations.
Charles A. Geoffrion
Charles joined Allied BioScience in 2008 as chief science officer after serving as associate vice president for research at the University of Arizona, as well as posts as the associate dean of science for corporate and external affairs and the campus research integrity officer. He is a member of the Pima County Board of Health and has experience in numerous public-private sector collaborations in America and internationally.
Daniel Moros, M.D.
Dr. Moros serves ABS as vice-chairman of scientific affairs. He is associate clinical professor of neurology at Icahn School of Medicine at Mount Sinai in New York City. His specialization is in movement disorders and behavioral neurology. He has spent many years in the pharmaceutical industry as vice chairman and medical director of Taro Pharmaceutical Co., Ltd. with responsibilities for generic and new drug development and regulatory affairs. In addition to being published in numerous publications in medical ethics and the philosophy of medicine, Dr. Moros has co-taught a graduate course in medical ethics at the City University of New York and Icahn School of Medicine for the last two decades.
George is a professional engineer (retired) with extensive experience in the refining and petrochemical sectors in the Far East, Europe and former Soviet Union. He served as vice president and general manager for a large engineering company in the Middle East. Peat sits on the University of British Columbia Chemical/Biological Engineering Industry Advisory Council, the advisory board of SG Biofuels, a developer of renewable biofuels in Latin and South America, and is on other for-profit and nonprofit boards. George has considerable experience with start-up companies. He serves as vice-chairman of international business development for ABS.
Dick brings over 45 years of experience in building successful, innovative companies. Prior to joining the board of Allied BioScience, Dick founded and cofounded a number of highly successful companies including Rothkopf Enterprises, Stand-buys, Learning Curve International and Ludorum. Dick also serves on a number of other corporate and not for profit boards and is a graduate of Cornell University.